Radiofrequency Ablation Devices Market Size - By Product Type (RF Generators, Consumables), By Application (Oncology, Cardiology, Cosmetic Surgery, Gynecology, Pain Management, Urology), By End-Use – Global Forecast (2023-2032)

Radiofrequency Ablation Devices Market Size

Radiofrequency Ablation Devices Market size was valued at USD 4.3 billion in 2022 and is estimated to account for USD 10.4 billion by 2032. Radiofrequency ablation is a medical technique that involves using high-frequency electrical currents to generate heat and target specific tissues in the body.
 

These devices are utilized to create controlled lesions or destroy abnormal tissue growths without the need for traditional open surgery. The radiofrequency ablation procedure is typically performed using specialized catheters or probes that deliver the radiofrequency energy to the intended area. The market is witnessing lucrative expansion because of the increasing prevalence of chronic diseases, rising demand for minimally invasive treatments, and advancements in medical technology. These devices offer several advantages, such as reduced patient recovery time, decreased risk of complications, and improved treatment outcomes.
 

Advancements in RF ablation technology will enhance the development of sophisticated and precise devices. As, modern RF ablation devices can accurately target specific tissues, tumors, or nerves, while minimizing damage to surrounding healthy tissues. This increased precision has improved treatment outcomes and reduced the risk of complications. Furthermore, the miniaturization of RF ablation devices and the development of more flexible and maneuverable catheters that provide ease of use for healthcare providers to access challenging anatomical locations, perform complex procedures, and improve patient comfort during the treatment.
 

Moreover, the integration of RF ablation devices with advanced medical imaging technologies such as ultrasound, CT scans, and MRI allows real-time visualization of the treatment area, enhancing accuracy and providing immediate feedback to the medical team during the procedure. Additionally, RF ablation devices offer multiple treatment modalities, combining radiofrequency energy with other techniques including microwave ablation or cryoablation for precise disease treatment.
 

COVID-19 Impact

The COVID-19 pandemic had a negative impact on the radiofrequency ablation devices market. During the pandemic, several healthcare facilities had to prioritize resources and focus on managing COVID-19 patients. This led to the postponement or cancellation of elective procedures, including radiofrequency ablation treatments for non-life-threatening conditions. Moreover, the pandemic disrupted supply chains, manufacturing, and distribution of medical devices. Numerous companies faced challenges in launching new and advanced radiofrequency ablation devices or expanding into new markets due to logistical and regulatory obstacles during the pandemic. In addition, several medical device companies redirected their research and development efforts toward creating solutions related to COVID-19, such as diagnostic tests, ventilators, and personal protective equipment.
 

Radiofrequency Ablation Devices Market Trends

The growing prevalence of chronic diseases such as cancer, cardiovascular devices, gynecological disorders, diabetes, and several others is a key factor driving the industry progression. The increasing prevalence rate of cardiac arrhythmias, such as atrial fibrillation and ventricular tachycardia with an aging population base will offer unprecedented expansion opportunities to the industry gains. For instance, the World Health Organization (WHO) reports that more than 17.9 million deaths globally each year are attributed to cardiovascular disorders, that stands for around 32% of overall mortality worldwide.
 

Also, the Centers for Disease Control and Prevention (CDC) estimated that 12.1 million people will suffer from atrial fibrillation by 2030 in the U.S. owing to the increase in number of heart disorders, the demand for radiofrequency ablation devices for cardiac ablation.  Further, radiofrequency ablation is commonly used in the treatment of cancerous tumors, particularly in the liver, kidney, lung, and bone. For instance, according to the World Health Organization (WHO) estimates, cancer is one of the leading causes of death in the majority of countries globally.
 

Radiofrequency Ablation Devices Market Analysis

The radiofrequency ablation devices market by product type is segregated into RF generators and consumables. The RF generators garnered more than USD 2.9 billion in revenue size in the year 2022. As the prevalence of chronic diseases such as cardiac arrhythmias, cancer, and chronic pain continues to rise globally, the demand for radiofrequency ablation procedures and consequently. Newer generations of RF generators are often equipped with advanced features such as real-time monitoring, impedance feedback systems, and optimized energy delivery algorithms, to enhance treatment outcomes and patient safety.
 

Based on application, the radiofrequency ablation devices market is classified into oncology, cardiology, cosmetic surgery, gynecology, pain management, urology, and others. The cardiology segment accounted for over 41% market share in 2022. A high surge in the prevalence of cardiac arrhythmias such as atrial fibrillation and ventricular tachycardia worldwide due to an aging population base and the growing prevalence of risk factors such as hypertension and diabetes. As the number of patients with arrhythmias increases, the demand for radiofrequency ablation devices for cardiac ablation procedures. Further, increasing awareness among physicians and cardiologists about the benefits and effectiveness of radiofrequency ablation for cardiac arrhythmias has led to greater adoption of the procedure.
 

Based on end-use, the radiofrequency ablation devices market is subdivided into hospitals, ambulatory surgical centers, and others. The hospitals segment is predicted to witness the highest growth at 9.3% CAGR by 2032 attributed to the aging demographics, growing hospital admissions, and high prevalence rate of chronic diseases burden. Moreover, the growing adoption of minimally invasive treatment options owing to their benefits including shorter hospital stays, faster patient recovery, and reduced risk of complications among hospitals. Further, hospitals are implementing collaborative care models involving multidisciplinary teams, including cardiologists, oncologists, pain management specialists, and several other experts.
 

U.S. radiofrequency ablation devices market accounted for USD 1.6 billion in revenue size in 2022. The increasing prevalence of chronic diseases such as cancer, diabetes and cardiovascular conditions in the U.S. population is predicted to spur the demand for radiofrequency ablation devices for effective treatment. Further, the strong presence of industry participants focusing on several innovations and continuous advancements in radiofrequency ablation devices, including ablation catheters, RF generators, and integration with medical imaging technologies. Additionally, the shift towards value-based healthcare, focusing on patient outcomes and cost-effectiveness will influence the adoption of radiofrequency ablation as a preferred treatment option in the U.S.
 

Radiofrequency Ablation Devices Market Share

Some of the prominent radiofrequency ablation devices market participants operating in the radiofrequency ablation devices industry include

• Avanos Medical, Inc.
• Stryker Corporation
• Abbott Laboratories, Inc.
• Medtronic, Plc.
• Boston Scientific Corporation
• Becton
• Dickinson and Company (Venclose, Inc.)
• AngioDynamics, Inc.
• Hologic, Inc.
• AtriCure, Inc.
• Koninklijke Philips N.V., Smith & Nephew
• Baylis Medical Company, Inc
• inomed Medizintechnik GmbH
• Sutter Medizintechnik GmbH
• Epimed International 
   

Radiofrequency Ablation Devices Industry News:

• In May 2023, Abbott Laboratories received approval for its TactiFlex ablation catheter by U.S. FDA. This advanced catheter is used with a next-gen RF ablation system for effective cardiac disease treatment such as atrial fibrillation and cardiac arrhythmia. Such approvals expanded the company’s product offerings in the significant market.
   
• In August 2022, Medtronic Plc. acquired Affera, Inc. Through this acquisition, Medtronic broadened its cardiac ablation product portfolio with a cardiac mapping and navigation platform with integration of radiofrequency and focal pulsed field ablation solutions to treat cardiac arrhythmia and atrial fibrillation.
   

Radiofrequency ablation devices market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2018 to 2032 for the following segments:

Click here to Buy Section of this Report

By Product Type (USD Million & Units)

• RF generators
• Consumables

By Application (USD Million)

• Oncology
• Cardiology
• Cosmetic surgery
• Gynecology
• Pain management
• Urology
• Others

By End-use (USD Million)

• Hospitals
• Ambulatory surgical centers
• Others

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Switzerland
  • The Netherlands
  • Denmark
  • Poland
  • Sweden
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • New Zealand
  • Thailand
  • Vietnam
  • Indonesia
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Chile
• Middle East & Africa
  • Saudi Arabia
  • South Africa
  • UAE
  • Turkey